Measuring Synovial Fluid Components

NCT ID: NCT05416255

Last Updated: 2024-04-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-04-01

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Participants with grade 3 and 4 knee osteoarthritis will recieve aspiration of synoivial fluid, and then receive either dextrose, hemaotopoietic stem cell, or platelet rich plasma, or no injection. The synovial fluid will be analyzed for changes in components.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

80 participants with grade 3 and 4 symptomatic knee osteoarthritis, with a visable effusion, will receive aspiration of 3 ml of synovial fluid from the suprapatellar pouch, followed by either injection with 10 mL of 12.5% dextrose, 10 cc hematopoietic stem cells, 10cc PRP, or no injection into the suprapatellar pouch. They will then receive aspiration of 3 ml of synovial fluid at 2 days and either 7 days (for dextrose injected or no injection) or 14 days (stem cell and PRP injected) days post injection. These synovial samples will be analyzed for a change in components.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Knee Osteoarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Consecutive patients treated for knee osteoathritis with dextrose injection, hemaopoietic stem cell injection, PRP injection, or no injection.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dextrose injection

Injection of 10 ml of 12.5% dextrose

Group Type ACTIVE_COMPARATOR

Measuring synovial fluid components

Intervention Type DIAGNOSTIC_TEST

Using speialized techniques to measure S.F. components

Hematopoietic stem cells

Injection of 10 ml of of 7.5 ml hematopoietic stem cells, 2 ml of 25% dextrose (5% diluted), 0.5 ml of 1% lidocaine (0.05% diluted),and 0.25 ml dexamethasone (1.5 mg)

Group Type ACTIVE_COMPARATOR

Measuring synovial fluid components

Intervention Type DIAGNOSTIC_TEST

Using speialized techniques to measure S.F. components

Platelet Rich Plasma injection

Injection of 10 ml of leukocyte rich platelet rich plasma

Group Type ACTIVE_COMPARATOR

Measuring synovial fluid components

Intervention Type DIAGNOSTIC_TEST

Using speialized techniques to measure S.F. components

No injection

Aspiration of synovial fluid may be an active comparator.

Group Type ACTIVE_COMPARATOR

Measuring synovial fluid components

Intervention Type DIAGNOSTIC_TEST

Using speialized techniques to measure S.F. components

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Measuring synovial fluid components

Using speialized techniques to measure S.F. components

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥ 6/10 on a 0-10 point numerical rating scale
* High grade medial compartment cartilage loss ( Kellgren-Lawrence grade 3 or 4) on plain weight bearing X-ray
* Exposed subchondral bone at 110 degrees of flexion by ultrasound examination
* Easily visible suprapatellar pouch with quads conttraction.

Exclusion Criteria

* Current intake of NSAIDs or steroids
* Current anticoagulation therapy
* Inflammatory or post-infectious knee arthritis
* Systemic inflammatory conditions
* Knee flexion less than 100 degrees
* Knee extension less than 165 degrees
* Valgus or varus more than 15 degrees
* Any knee injection in the precedign 3 months
* BMI more than 50 kg/ meter squared
* Gross synovial folds on ultrasound.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Dharma Bioscience

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gastón Andres Topol

Treating physician and primary investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dharma Centro de Medicina Regenerativa

Rosario, Santa Fe Province, Argentina

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Argentina

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SFComponents#1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Evaluation of Biomarkers in Human Synovial Fluid
NCT02664870 ACTIVE_NOT_RECRUITING